Editorial
What Can Change my Practice After Evaluate Progress that I Heard at the Meeting of the ASCO 2017?
Adrian Pablo Hunis1,2,3,4,*1Board Certified in Medical Oncology, School of Medicine University of Buenos Aires, Argentina
2Carrer Specialist in Oncology, School of Medicine
3University of Buenos Aires (UBA), Argentina
4Head Professor of Oncology, Maimonides University, Argentina
- *Corresponding Author:
- Adrián Pablo Huñis
Board Certified in Medical Oncology, Assistant Professor of Internal Medicine
School of Medicine, University of Buenos Aires, Argentina
Tel: 4981-1128
E-mail: aphunis@gmail.com
Received date: July 2, 2017; Accepted date: July 5, 2017; Published date: July 15, 2017
Citation: Hunis AP (2017) What Can Change my Practice After Evaluate Progress that I Heard at the Meeting of the ASCO 2017? Adv Cancer Prev 2:e106. doi:10.4172/2472-0429.1000e106
Copyright: © 2017 Huñis AP. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Advances in personalized medicine for the management of numerous tumors and confirmation immunotherapy as a weapon fundamental in the treatment of cancer has starred Congress of the American Society of Clinical Oncology (ASCO), which was carried out in the city of Chicago, between June, 2-6 past.